Pancreatic Cancer Research

ResearcherThe University of Texas Health Science Center at HoustonActive in the last 2 years

Majid Momeny

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7755-0826; OpenAlex author ID A5090828119. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics18080920↗
  2. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1007/s13402-019-00473-9↗
  3. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1007/s13402-019-00448-w↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.29
  2. Ali Azhdarinia · 1 shared paper, 2026 · strength 0.29
  3. Vahid Khalaj · 1 shared paper, 2026 · strength 0.29
  4. MacKenzie V. Demmel · 1 shared paper, 2026 · strength 0.29
  5. Jennifer M. Bailey · 1 shared paper, 2026 · strength 0.29
  6. Seyed Hamidollah Ghaffari · 2 shared papers, 2019–2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.